home / stock / tsvt / tsvt quote
Last: | $2.35 |
---|---|
Change Percent: | -0.47% |
Open: | $2.16 |
Close: | $2.35 |
High: | $2.46 |
Low: | $2.15 |
Volume: | 1,860,731 |
Last Trade Date Time: | 12/06/2023 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.35 | $2.16 | $2.35 | $2.46 | $2.15 | 1,860,731 | 12-06-2023 |
$2.15 | $2.05 | $2.15 | $2.205 | $2.0235 | 1,312,723 | 12-05-2023 |
$2.06 | $1.94 | $2.06 | $2.21 | $1.92 | 1,681,789 | 12-04-2023 |
$1.94 | $1.83 | $1.94 | $1.95 | $1.675 | 775,214 | 12-01-2023 |
$1.83 | $1.95 | $1.83 | $2.0156 | $1.82 | 1,542,094 | 11-30-2023 |
$1.92 | $1.95 | $1.92 | $2.085 | $1.89 | 826,307 | 11-29-2023 |
$1.88 | $1.9 | $1.88 | $1.92 | $1.75 | 1,235,703 | 11-28-2023 |
$1.82 | $1.78 | $1.82 | $1.8904 | $1.73 | 5,599,439 | 11-27-2023 |
$1.77 | $1.69 | $1.77 | $1.895 | $1.6803 | 923,203 | 11-24-2023 |
$1.74 | $1.62 | $1.74 | $1.74 | $1.535 | 3,247,901 | 11-23-2023 |
$1.74 | $1.62 | $1.74 | $1.74 | $1.535 | 3,247,901 | 11-22-2023 |
$1.57 | $1.75 | $1.57 | $1.75 | $1.55 | 1,787,587 | 11-21-2023 |
$1.74 | $1.88 | $1.74 | $1.9 | $1.65 | 8,180,244 | 11-20-2023 |
$2.13 | $2.21 | $2.13 | $2.31 | $2.045 | 1,249,503 | 11-17-2023 |
$2.115 | $2.38 | $2.115 | $2.38 | $2.07 | 1,870,850 | 11-16-2023 |
$2.33 | $2.28 | $2.33 | $2.5 | $2.26 | 1,147,550 | 11-15-2023 |
$2.28 | $2.15 | $2.28 | $2.65 | $1.889 | 1,898,575 | 11-14-2023 |
$2.26 | $2.18 | $2.26 | $2.27 | $2.01 | 885,094 | 11-13-2023 |
$2.18 | $2.32 | $2.18 | $2.32 | $2.16 | 1,044,173 | 11-10-2023 |
$2.26 | $2.3 | $2.26 | $2.375 | $2.195 | 662,571 | 11-09-2023 |
News, Short Squeeze, Breakout and More Instantly...
2seventy bio Inc. Company Name:
TSVT Stock Symbol:
NASDAQ Market:
2023-12-06 14:48:10 ET Penny Stocks – How News Makes These Small Caps Soar or Plunge Penny stocks , securities with share prices under $5, offer investors a chance at exponential returns with little upfront investment. However, investing wisely in penny stocks require...
2seventy bio, Inc. (NASDAQ: TSVT), (“2seventy” or “the Company”), a leading immuno-oncology cell therapy company, today issued the following statement reiterating its commitment to maximizing shareholder value: As we indicated last month, the Board has commenced a ...
Tuesday, the FDA said it received reports of patients developing T-cell malignancies, including chimeric antigen receptor CAR-positive ly...